Articles by Leah Sherwood
At EHA 2024, Dr. Santini shares data on luspatercept and imetelstat in patients with MDS and anemia.
Dr. Garcia-Manero discusses the latest updates from the COMMANDS trial.
Dr. Garcia-Manero discussed luspatercept, a first-in-class drug for patients with low-risk MDS and anemia.
Dr. DeZern discusses how medicine has changed and shares some advice for early-career clinicians.
The SOHO 2024 Annual Meeting will take place September 4-7, 2024, in Houston, Texas.
The foundation conducts partnerships with companies to provide funding to accelerate novel blood cancer therapies.
Dr. Martin highlighted research in quadruplet therapy, CAR-T therapy, and bispecific T-cell engagers.
The Beat AML trial has provided practice-changing insights and allows investigators to assess the potential of novel agents.
Acalabrutinib and zanubrutinib demonstrated better safety and efficacy outcomes when compared with ibrutinib in CLL/SLL.
The expert panel discusses current issues in the use of ESAs within MDS management.
In a roundtable discussion, an expert panel discussed how approval of luspatercept has affected frontline MDS treatment.
Julie Braish, MBBCh, discusses her study on JAK2 allele burden in myelofibrosis presented at ASCO 2024.
The authors reported clinically meaningful responses of luspatercept treatment from patients enrolled in the COMMANDS trial.
The SOHO 2024 Annual Meeting will take place September 4-7, 2024, at the George R. Brown Convention Center in Houston, Texas.
The 15-month PFS was approximately 33% for patients who were BTK exposed and over 50% for patients who were BTK naïve.
The expert panel describes how having two separate classification systems for MDS affects their clinical practices.
The expert panel discusses how to explain to patients the range of MDS severities and approach lower-risk disease.
The expert panel discusses molecular testing's current place in MDS evaluation and treatment decisions.
Dr. Rampal, of Memorial Sloan Kettering Cancer Center, discusses his abstract at the EHA 2024 Congress in Madrid, Spain.
After five and a half years of follow-up, rituximab maintenance significantly improved survival outcomes.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.